Canagliflozin use does not significantly reduce MI risk in diabetics: Study
Australia: The use of SGLT2 inhibitor canagliflozin does not significantly reduce the risk of myocardial infarction (MI) in the population of CANVAS Program and CREDENCE trial, finds a recent study. The study, published in the journal Cardiovascular Research, included patients with type 2 diabetes and history or high risk of cardiovascular disease (CANVAS Program) or type 2 diabetes and chronic kidney disease (CREDENCE).
Gemma A Figtree, University of Sydney, Sydney, Australia, and colleagues aimed to explore the potential impact of sodium glucose co-transporter 2 inhibition (SGLT2i) on the clinical features of patients presenting with myocardial infarction (MI) through a post-hoc analysis of CANVAS Program and CREDENCE trial given the benefit of SGLT2i.
The study included people with type 2 diabetes and history or high risk of cardiovascular disease (CANVAS Program) or type 2 diabetes and chronic kidney disease (CREDENCE). They were randomized to receive Canagliflozin 100 or 300 mg (combined in the analysis) or placebo.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.